MEDICATIONS DEVELOPMENT FOR THE TREATMENT OF CANNABIS RELATED DISORDERS

治疗大麻相关疾病的药物开发

• 批准号: 8167200
• 负责人: Heather May Haughey
• 金额: $ 20.45万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167200
• 关键词: Behavioral; Cannabis; Cannabis-Related Disorder; Cigarette; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cues; Development; Disease; Dose; Drug Addiction; Etiology; Foundations; Funding; Grant; Human; Individual; Institution; Intervention Studies; Laboratory Study; Literature; Marijuana Dependence; Neuromodulator; Oral; Pharmaceutical Preparations; Pharmacotherapy; Placebos; Play; Procedures; Psychological reinforcement; Randomized; Reporting; Research; Research Personnel; Resources; Role; Smoke; Smoker; Source; Stress; Substance P Receptor; Substance-Related Disorders; System; Therapeutic; Tobacco; United States National Institutes of Health; Withdrawal Symptom; aprepitant; base; craving; design; response; therapeutic development; therapy development; treatment strategy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. One of NIDA's highest priorities for funding is the development of effective pharmacotherapies for substance related disorders. In response to RFA-DA-09-005, soliciting pilot clinical/human studies of interventions that specifically target mechanisms known to play an important role in the etiology of drug addiction, we propose to perform a pilot clinical trial of medication to target a neuromodulator of stress in the CNS, the neurokinin 1 (NK1) receptor system. Based on inferences from recent reports in the scientific literature, the NK1 receptor system is a new potential therapeutic treatment strategy for the cessation of cannabis use in individuals who also smoke tobacco. We hypothesize that the NK1 receptor antagonist, aprepitant, will be safe, tolerable and efficacious at reducing the withdrawal symptoms, cue craving, and reinforcement value for both cannabis and tobacco resulting from the cessation of either or both drugs. We will assess this hypothesis in the context of a carefully controlled human laboratory study in which subjects (N=72) will be randomized in a 3 x 2 factorial design to one of 3 behavioral conditions; a) withdrawn from both substances, b) withdrawn from tobacco only, or c) withdrawn from cannabis only, and to receive one of 2 medication dose conditions: placebo or aprepitant (160 mg/day). Medication will be administered for 5 days, followed by a cue challenge, choice procedure, and then a consequence (i.e., oral cannabis or a cigarette or money) also on day 5. The scientific significance is that NK1 receptor antagonists promise to be an important new target for the development of therapeutic medications for treating heavy cannabis smokers. The results of our human laboratory study will lay the foundation for subsequent clinical trials of aprepitant for the treatment of cannabis dependence among individuals who smoke tobacco for the alleviation of either or both concurrent disorders.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 NIDA的最高优先事项之一是开发有关物质相关疾病的有效药物治疗。 为了响应RFA-DA-09-005，征求了对干预措施的试验临床/人类研究，这些干预措施专门针对已知的机制在药物成瘾的病因中起重要作用，我们建议对药物进行试验性临床试验，以靶向CNS中的压力神经调节剂，在CNS，Neurokinin 1（Neurokinin 1（NK1）受体中。 根据科学文献最新报告的推论，NK1受体系统是一种新的潜在治疗治疗策略，用于停止在也吸烟的个体中使用大麻的使用。 我们假设NK1受体拮抗剂Aprepitant将在减少大麻和两种药物停止造成的大麻和烟草的戒断症状，​​提示和增强价值方面是安全，可忍受和有效的。 我们将在经过仔细控制的人类实验室研究的背景下评估这一假设，在该研究中，在3 x 2阶乘设计中，受试者（n = 72）将随机分为3种行为条件之一。 a）从这两种物质中撤回，b）仅从烟草中撤出，或c）仅从大麻中撤出，并接受2种药物剂量疾病之一：安慰剂或同胞（160 mg/day）。 还将在第5天进行5天的药物服用5天，然后进行提示挑战，选择程序，然后是结果（即口服大麻或香烟或金钱）。科学意义在于，NK1受体拮抗剂有望成为用于治疗大麻烟的治疗药物开发的重要新目标。 我们的人类实验室研究的结果将为随后在吸烟烟草中减轻任何一种或两种并发疾病的人的治疗大麻依赖的临床试验奠定基础。